In prostate cancer, FAP+ stromal programmes co‐occur with immunosuppressive myeloid states (e.g., CD163+/SPP1+ macrophages) [54] and FAP itself can also promote macrophage activation and tissue remodelling [55]. The gene discussed is SPP1; the disease is prostate carcinoma.